Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurocrine Biosciences' partner Abbott has commenced a Phase II trial to investigate elagolix as a treatment for uterine fibroids.
Subscribe to our email newsletter
With the initiation of this trial, Abbott has paid a $10m milestone payment to Neurocrine.
Neurocrine president and CEO Kevin Gorman said they are pleased that their collaboration has reached this important milestone with elagolix now being evaluated in a clinical setting for use in treating uterine fibroids.
"We look forward to a continued successful collaboration with Abbott," Gorman said.